Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Elevance Health Inc. pages available for free this week:
- Statement of Comprehensive Income
- Cash Flow Statement
- Analysis of Reportable Segments
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Selected Financial Data since 2005
- Return on Assets (ROA) since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Elevance Health Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The solvency position of the company, as indicated by the provided ratios, exhibits a generally stable profile with some emerging trends over the observed period. Throughout 2022, the ratios remained relatively consistent. However, from early 2023 through the end of 2025, subtle shifts are apparent, suggesting a moderate change in the company’s financial leverage and ability to cover its interest obligations.
- Debt to Equity
- The debt to equity ratio demonstrated stability between 0.65 and 0.68 from March 2022 to December 2023. A slight decrease to 0.62 was observed in September 2024, followed by an increase to 0.76 in December 2024. This upward movement continued into 2025, reaching 0.73 by December, indicating a growing reliance on debt financing relative to equity.
- Debt to Capital
- The debt to capital ratio remained consistently below 0.42 throughout most of the period, fluctuating between 0.38 and 0.41. A noticeable increase to 0.43 occurred in December 2024, maintaining at 0.42 by the end of 2025. This suggests a gradual increase in the proportion of debt used to finance the company’s assets.
- Debt to Assets
- The debt to assets ratio remained relatively stable around 0.23 to 0.24 for the majority of the period. A gradual increase was observed, culminating in a ratio of 0.27 in December 2024, and holding steady at 0.26 through December 2025. This indicates a slowly increasing level of debt financing relative to the company’s total assets.
- Financial Leverage
- Financial leverage, as measured by the ratio, fluctuated between 2.66 and 2.92. The ratio generally decreased from 2.92 in March 2023 to 2.66 in June 2024, before increasing again to 2.77 by December 2025. This suggests a moderate change in the company’s use of debt to amplify returns, with a slight increase in leverage towards the end of the period.
- Interest Coverage
- The interest coverage ratio experienced a consistent downward trend throughout the period. Starting at 11.01 in March 2022, it decreased to 5.79 by December 2025. This decline indicates a diminishing ability to cover interest expenses from earnings, potentially signaling increased financial risk. The rate of decline accelerated in the latter half of the period, with more substantial decreases observed from September 2023 onwards.
In summary, while the company maintained a reasonable solvency position for much of the observed period, the latter portion reveals a trend of increasing debt utilization and a decreasing ability to comfortably cover interest obligations. These developments warrant continued monitoring to assess their potential impact on the company’s long-term financial health.
Debt Ratios
Coverage Ratios
Debt to Equity
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||
| Long-term debt, less current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Shareholders’ equity | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio for the analyzed period demonstrates a generally stable trend with some notable fluctuations, particularly towards the end of the observed timeframe. Initially, the ratio exhibited a slight increasing trend, followed by a period of relative stability, and then a more pronounced increase in the latter quarters.
- Overall Trend
- The debt to equity ratio began at 0.65 in March 2022 and remained relatively consistent, fluctuating between 0.64 and 0.68 for the subsequent six quarters. A clear upward trend emerges from December 2023, reaching 0.76 in December 2024, before stabilizing around 0.73 in the final two quarters presented.
- Initial Period (Mar 31, 2022 – Jun 30, 2023)
- From March 2022 to June 2023, the ratio increased from 0.65 to 0.66, then decreased slightly to 0.65. This suggests a modest increase in leverage during this period, but within a narrow range. The fluctuations were minimal, indicating a relatively consistent capital structure.
- Period of Stability (Sep 30, 2023 – Mar 31, 2024)
- The ratio remained relatively stable between 0.64 and 0.66 from September 2023 through March 2024. This indicates a period where the company maintained a consistent balance between debt and equity financing.
- Significant Increase (Apr 30, 2024 – Dec 31, 2024)
- A substantial increase in the debt to equity ratio is observed from April 2024, rising from 0.66 to 0.76 by December 2024. This suggests a significant increase in debt relative to equity during this period, potentially indicating increased reliance on debt financing or a decrease in equity.
- Recent Period (Jan 31, 2025 – Jun 30, 2025)
- The ratio stabilized in the most recent two quarters, holding steady at approximately 0.73. While elevated compared to earlier periods, the stabilization suggests the company may have paused further increases in leverage.
The observed increase in the debt to equity ratio warrants further investigation to understand the underlying reasons, such as increased borrowing for expansion, share repurchases, or changes in profitability. The recent stabilization may indicate a deliberate effort to manage leverage at the current level.
Debt to Capital
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||
| Long-term debt, less current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Shareholders’ equity | |||||||||||||||||||||
| Total capital | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio for the analyzed period demonstrates a generally stable trend with a slight increase towards the end of the observed timeframe. Throughout much of the period, the ratio remains within a narrow band, indicating a consistent capital structure. However, a discernible shift occurs in the later quarters, warranting further examination.
- Overall Trend
- The debt to capital ratio begins at 0.39 in March 2022 and fluctuates modestly around this level for the subsequent six quarters, remaining below 0.41. A gradual increase is then observed, culminating in a ratio of 0.43 in December 2024. The ratio stabilizes slightly in the following quarters, ending at 0.42 in December 2025.
- Short-Term Fluctuations
- From March 2022 to September 2022, the ratio experiences a slight increase from 0.39 to 0.40, suggesting a modest increase in leverage. This is followed by a period of stability through December 2023, where the ratio remains consistently at 0.39 or 0.40. The most significant change occurs between September 2024 (0.38) and December 2024 (0.43), representing a notable increase in the proportion of debt relative to capital.
- Long-Term Perspective
- Over the entire analyzed period, the debt to capital ratio increases from 0.39 to 0.42. While not a dramatic shift, this indicates a growing reliance on debt financing relative to equity and other forms of capital. The increase is particularly pronounced in the latter half of the period, suggesting a potential change in the company’s financing strategy or capital allocation decisions.
- Total Debt and Total Capital
- Total debt increased from US$23,255 million in March 2022 to US$32,046 million in December 2025, representing a substantial absolute increase. Total capital also increased, from US$59,230 million to US$75,928 million over the same period. The increase in debt, however, outpaced the increase in capital, contributing to the observed rise in the debt to capital ratio.
In conclusion, the debt to capital ratio indicates a generally stable, but ultimately increasing, level of financial leverage. The recent increase warrants continued monitoring to assess its potential impact on the company’s financial flexibility and risk profile.
Debt to Assets
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||
| Long-term debt, less current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt-to-assets ratio for the analyzed period demonstrates a generally stable profile with a slight increasing trend towards the end of the observed timeframe. Throughout much of the period, the ratio remains consistently around 0.23, indicating that approximately 23% of assets are financed by debt. However, more recent quarters show a gradual increase in this ratio.
- Overall Trend
- The ratio exhibits relative stability from March 31, 2022, through September 30, 2023, fluctuating between 0.22 and 0.23. A noticeable upward trend begins in December 2023, continuing through December 2025. This suggests an increasing reliance on debt financing relative to the asset base.
- Short-Term Fluctuations
- A minor dip to 0.22 is observed in September 2023, potentially due to asset revaluation or debt repayment. However, this is a temporary deviation from the prevailing trend. The ratio returns to 0.23 in December 2023 before beginning its ascent.
- Recent Increases
- From December 2023 (0.23) to December 2024 (0.27), the ratio increases by 4 percentage points. This represents the most significant change within the analyzed period. The ratio stabilizes at approximately 0.26 in the final two quarters, indicating a potential plateau in the increased debt leverage. The increase from 0.24 in March 2024 to 0.27 in December 2024 is particularly noteworthy.
- Total Debt and Assets
- The increase in the debt-to-assets ratio is driven by a faster growth rate in total debt compared to total assets. While both metrics generally increase over time, the growth in total debt accelerates in the latter half of the period, contributing to the rising ratio. Total debt increased from US$25.124 billion in June 2023 to US$32.046 billion in December 2025, while total assets increased from US$109.168 billion in June 2023 to US$121.494 billion in December 2025.
In conclusion, the debt-to-assets ratio indicates a strengthening of financial leverage over the analyzed period, particularly in the most recent quarters. While the ratio remains within a reasonable range, the upward trend warrants continued monitoring to assess potential risks associated with increased debt financing.
Financial Leverage
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Shareholders’ equity | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
Financial leverage, as indicated by the ratio of total assets to shareholders’ equity, exhibited a generally stable pattern over the observed period, with some fluctuations. The ratio began at 2.79 in March 2022 and generally increased through the end of 2023 before decreasing slightly and stabilizing again.
- Overall Trend
- From March 2022 to December 2023, the financial leverage ratio generally trended upwards, increasing from 2.79 to 2.77. This suggests a gradual increase in the proportion of assets financed by debt or other liabilities relative to equity during this period. Following December 2023, the ratio decreased to 2.68 by June 2024, before increasing again to 2.77 by December 2025.
- Peak and Trough Values
- The highest recorded financial leverage ratio was 2.92, observed in March 2023. The lowest ratio was 2.66, recorded in June 2024. These represent the periods of highest and lowest reliance on external financing relative to equity.
- Recent Performance
- In the most recent periods analyzed, the ratio has remained relatively stable, fluctuating between 2.79 and 2.77 from September 2025 to December 2025. This suggests a period of consistent capital structure management.
- Year-over-Year Comparison
- Comparing March 2022 (2.79) to March 2025 (2.82), a slight increase in financial leverage is observed. Similarly, comparing June 2022 (2.82) to June 2025 (2.79), a slight decrease is observed. These changes suggest minimal shifts in the company’s overall financial structure over the three-year period.
The observed fluctuations in financial leverage appear moderate and do not indicate any dramatic shifts in the company’s financing strategy. The ratio remains within a relatively narrow range throughout the analyzed timeframe.
Interest Coverage
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Shareholders’ net income | |||||||||||||||||||||
| Add: Net income attributable to noncontrolling interest | |||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||
| Add: Interest expense | |||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Interest coverage
= (EBITQ4 2025
+ EBITQ3 2025
+ EBITQ2 2025
+ EBITQ1 2025)
÷ (Interest expenseQ4 2025
+ Interest expenseQ3 2025
+ Interest expenseQ2 2025
+ Interest expenseQ1 2025)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The interest coverage ratio for the analyzed period demonstrates a generally declining trend, although with some quarterly fluctuations. Initially strong, the ratio exhibits a consistent erosion of the company’s ability to meet its interest obligations from earnings before interest and taxes. This analysis details the observed patterns and potential implications.
- Overall Trend
- From March 31, 2022, through December 31, 2025, the interest coverage ratio decreased from 11.01 to 5.79. This represents a substantial reduction in the cushion available to cover interest expenses. The decline is not linear, with periods of stabilization or slight improvement interspersed within the overall downward trajectory.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The ratio remained relatively stable during the first three quarters of 2022, fluctuating between 10.71 and 11.01. A slight decrease was observed in the final quarter of 2022, falling to 10.13, indicating a modest reduction in the ability to cover interest expense.
- 2023 Performance
- 2023 witnessed a more pronounced decline. The ratio started at 9.95 in March and progressively decreased throughout the year, reaching 8.49 by December. This suggests increasing pressure on earnings relative to interest obligations during this period.
- 2024 and 2025 – Accelerated Decline
- The rate of decline accelerated in 2024, with the ratio falling from 8.70 in March to 7.67 in December. This trend continued into 2025, culminating in a ratio of 5.79 by December. The most significant drop occurred between September 2025 (6.16) and December 2025 (5.79). This indicates a substantial weakening in the company’s capacity to service its debt from current earnings.
- EBIT and Interest Expense Relationship
- While both EBIT and interest expense experienced fluctuations, the interest expense consistently increased over the period. The decrease in the interest coverage ratio is attributable to a combination of decreasing EBIT in several quarters and a steady rise in interest expense. The relative growth of interest expense appears to have outpaced the growth, or even the maintenance, of EBIT.
The observed trend warrants further investigation into the underlying drivers of both EBIT and interest expense. A continued decline in the interest coverage ratio could signal increasing financial risk and potentially limit the company’s financial flexibility.